However, the effect of initiating TfRMAb-TNFR treatment in older APP/PS1 mice when the AD pathology is full-blown, and its safety profile following chronic administration in comparison to TfRMAb alone, have not been studied and were the focus of the current investigation. Here, TNFRSF1A is linked to Alzheimer disease.